Novo Holdings Wants to Do More China Biotech Deals, CEO Says
Novo Holdings, the controlling shareholder of Danish weight-loss drug pioneer Novo Nordisk A/S, is seeking more biotech transactions in China following two deals last year for the overseas rights to experimental medicines.
